Fresenius Kabi
- Country
- 🇧🇪Belgium
- Ownership
- Subsidiary
- Established
- 1999-01-01
- Employees
- -
- Market Cap
- -
Clinical Trials
51
Trial Phases
4 Phases
Drug Approvals
18
Drug Approvals
- Prev
- 1
- 2
- Next
Clinical Trials
Distribution across different clinical trial phases (39 trials with phase data)• Click on a phase to view related trials
Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients with PNAC Who Require More Than Eight Weeks of Omegaven Treatment
- Conditions
- Parenteral Nutrition Associated Liver Disease (PNALD)Essential Fatty Acid DeficiencyMalnutritionPediatric ALL
- Interventions
- First Posted Date
- 2024-02-23
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- Fresenius Kabi
- Target Recruit Count
- 40
- Registration Number
- NCT06274788
- Locations
- 🇺🇸
University of California Los Angeles, Los Angeles, California, United States
🇺🇸Memorial Health Service, Fountain Valley, California, United States
🇺🇸Board of Regents of the University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
Safety Study of SMOFlipid to Evaluate the Risk of Developing EFAD and/or PNAC in Pediatric and Adult Patients
- Conditions
- Malnutrition, ChildMalnutritionEssential Fatty Acid Deficiency (EFAD)Parenteral Nutrition Associated Cholestasis
- Interventions
- Drug: SMOFlipid® (lipid injectable emulsion)
- First Posted Date
- 2023-09-22
- Last Posted Date
- 2025-08-20
- Lead Sponsor
- Fresenius Kabi
- Target Recruit Count
- 100
- Registration Number
- NCT06049680
- Locations
- 🇺🇸
Emory University Hospital, Atlanta, Georgia, United States
🇺🇸The University of Chicago, Chicago, Illinois, United States
🇺🇸Riley Hospital for Children, Indianapolis, Indiana, United States
Efficacy and Safety of SmofKabiven Extra Nitrogen for Parenteral Nutrition in Patients Receiving Intensive Care
- Conditions
- Nutrition TherapyCritical Illness
- Interventions
- First Posted Date
- 2022-02-25
- Last Posted Date
- 2024-02-21
- Lead Sponsor
- Fresenius Kabi
- Target Recruit Count
- 56
- Registration Number
- NCT05257031
- Locations
- 🇷🇺
Municipal Clinical Hospital No. 40 of Moscow Healthcare Department, Moscow, Russian Federation
bIosimilar of aDalimumab, an European evAluation
- Conditions
- Ulcerative ColitisRheumatoid ArthritisAnkylosing SpondylitisPsoriatic ArthritisCrohn Disease
- First Posted Date
- 2022-01-13
- Last Posted Date
- 2022-01-13
- Lead Sponsor
- Fresenius Kabi
- Target Recruit Count
- 1050
- Registration Number
- NCT05190484
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
- Conditions
- Ankylosing SpondylitisUlcerative ColitisPsoriatic ArthritisCrohn DiseaseRheumatoid ArthritisPsoriasis
- First Posted Date
- 2021-09-21
- Last Posted Date
- 2023-07-19
- Lead Sponsor
- Fresenius Kabi
- Target Recruit Count
- 754
- Registration Number
- NCT05051943
- Locations
- 🇫🇷
CHRU de Nancy - Hôpitaux de Brabois, Vandœuvre-lès-Nancy, France
- Prev
- 1
- 2
- 3
- 4
- 5
- 10
- Next
News
CivicaScript Announces Low-Cost Ustekinumab Biosimilar Distribution to Expand Access to Inflammatory Disease Treatment
CivicaScript will distribute ustekinumab-aauz biosimilar starting January 1, 2026, targeting chronic inflammatory conditions including plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.
Polpharma Biologics and Fresenius Kabi Partner on Vedolizumab Biosimilar for Inflammatory Bowel Disease
Polpharma Biologics has signed a global licensing agreement with Fresenius Kabi for PB016, a proposed biosimilar to Entyvio (vedolizumab) targeting moderate-to-severe ulcerative colitis and Crohn's disease.
Teva Partners with Formycon to Commercialize Stelara Biosimilar Fymskina in Germany
Formycon AG has entered into a distribution agreement with Teva's subsidiary Ratiopharm for the semi-exclusive commercialization of its Stelara biosimilar FYB202, branded as Fymskina, in Germany.
Tocilizumab Biosimilar CT-P47 Demonstrates Long-Term Efficacy and Safety in Rheumatoid Arthritis Treatment
CT-P47, a tocilizumab biosimilar, showed comparable efficacy and safety to reference Actemra over 52 weeks in a phase 3 trial involving 444 rheumatoid arthritis patients.
Fresenius Kabi Launches First Generic Iodixanol Contrast Agent in Canada, Addressing Critical Supply Shortages
Fresenius Kabi Canada launched Iodixanol Injection 270 and 320, marking the first generic injectable iodinated contrast media available in the Canadian market.
mAbxience Expands European Biosimilar Access Through Strategic Partnerships with Abiogen Pharma and Corapharm
mAbxience has signed two strategic licensing agreements to commercialize biosimilar candidates across Italy and Southeast Europe, partnering with Abiogen Pharma and Corapharm respectively.
Fresenius Kabi Launches Tyenne®, Canada's First Tocilizumab Biosimilar for Autoimmune Conditions
Fresenius Kabi has commercially launched Tyenne®, the first and only tocilizumab biosimilar available in Canada, offered in both subcutaneous and intravenous formulations.
Fresenius Kabi Launches 30 mg/30 mL Epinephrine Injection for Emergency Care and Septic Shock
Fresenius Kabi has introduced Epinephrine Injection, USP, in 30 mg per 30 mL multi-dose vials in the United States, expanding its emergency medicine portfolio.
Smart Drug Delivery Systems Market Poised for 17% Growth as Chronic Disease Management Evolves
The global smart drug delivery systems market reached $12 billion in 2024 and is projected to grow at a CAGR of 17% through 2034, driven by rising chronic disease prevalence and technological advancements.
Pacira BioSciences Settles EXPAREL Patent Litigation with Fresenius Kabi, Securing Market Exclusivity Until 2030
Pacira BioSciences has reached a settlement with Fresenius Kabi and other companies regarding patent litigation for its non-opioid pain therapy EXPAREL, allowing limited generic entry beginning in early 2030.